From Neurology Advisor: Nabiximols, a cannabidiol, reduced spasticity symptoms and was tolerable and safe when used in patients with motor neuron disease, according to a phase 2 trial published in Lancet Neurology. In this randomized, double-blind study (ClinicalTrials.gov identifier: NCT01776970), patients with possible, probable, or definite amyotrophic lateral sclerosis or
The use of a cannabis spray as part of the treatment plan for certain patients with cancer is taking another step forward with the announcement of continued clinical research by the New South Wales-based Medlab Clinical LTD. The phase I study is being led by Professor Stephen Clarke and has
On December 8, 2018, the following NIH-sponsored proceeding took place: “Evaluating the Therapeutic Potential of Cannabinoids: How to conduct research within the current regulatory framework“ From the website: The National Center for Complementary and Integrative Health (NCCIH), at the National Institutes of Health (NIH), sponsored a workshop on December 8,
In a focused effort to study the potential impact cannabinoid-based medical interventions may have on reducing opioid use for pain reduction, Perth-based Zelda Therapeutics LTD has established a partnership with St. Vincent’s Hospital in Melbourne to conduct clinical trials to study potential uses for these treatments. Subjects who have become
In spite of legalization of cannabis happening throughout much of the U.S. and full legalization in Canada, the state of medical research of cannabis is lagging behind in the United States. Legalization in other countries has paved the way for much easier access to research and standardization in the industry.
According to a recent report, clinical trials have begin at the University of Mississippi Medical Center to study the use of cannabidiol (also known as CBD) for the treatment of children with severe epilepsy. The initial trial will involve ten children from Mississippi with severe cases of epilepsy. Harper Grace’s Law,